Several investigations reported significantly higher percentages of CD4+CD25+FoxP3+ Tregs in patients with advanced metastatic NSCLC compared to healthy donors (141–144), whereas the high percentage of CD152+CD4+CD25highFoxP3+ Tregs is correlated with a more advanced stage of disease (141, 145). This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.